The ASK Biosimilars Real-World Evidence (RWE) programme launched in November 2022 is nearing completion with the final assets scheduled to go live next month.
The ASK Biosimilars Real-World Evidence project shares the latest data surrounding oncology biosimilars through resources including an abstract library summarising the latest published papers, as well as discussing outcomes of adopting biosimilars into different healthcare systems.
Developed with global as well as returning regional experts, the ASK RWE programme features resources that can be shared with the oncology multidisciplinary team. The ASK biosimilars website hosts 5 regional case studies reflecting on biosimilar adoption in Canada, United Kingdom, Italy, Australia, and America. These individual booklets are downloadable and feature on the website as part of the new ‘Education hub’.
The final case study launching in May will provide a global perspective on oncology biosimilar implementation, the switching process and economic impact. The global case study was developed with Jatinder Harchowal MBE (Chief Pharmacist at University College London Hospitals NHS Foundation Trust), who has also provided a foreword on the overall context which will introduce the full compendium encompassing all three sections of the abstract library and a glossary, also available to view and download in May.
The ASK RWE programme’s resources is marketed to our oncology multi-disciplinary community (oncologists, hospital pharmacists, secondary care nurses, advanced practice providers, and payors) via Cogora key media brands, as well as our expert faculty and worldwide societies.
The marketing campaign has led to fantastic engagement across the oncology multi-disciplinary community with over 13,000 pageviews of the newly launched campaign exceeding set KPIs. Explore the programme and educational resources on the ASK Biosimilars website.